News

Paycor’s (NASDAQ:PYCR) Q4 Sales Top Estimates

Online payroll and human resource software provider Paycor (NASDAQ:PYCR) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 13.1% year on year to $180.4 million. Its non-GAAP profit of $0.14 per share was 21.3% above analysts’ consensus estimates.

American Superconductor (NASDAQ:AMSC) Delivers Impressive Q4, Stock Soars

American Superconductor Corporation (AMSC) is a leading provider of megawatt-scale power resiliency solutions for the electrical grid and critical naval systems. beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 56% year on year to $61.4 million. On top of that, next quarter’s revenue guidance ($61 million at the midpoint) was surprisingly good and 3.1% above what analysts were expecting. Its non-GAAP profit of $0.16 per share was significantly above analysts’ consensus estimat

Align Technology (NASDAQ:ALGN) Reports Q4 In Line With Expectations But Stock Drops

Dental technology company Align Technology (NASDAQ:ALGN) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4% year on year to $995.2 million. On the other hand, next quarter’s revenue guidance of $975 million was less impressive, coming in 5.5% below analysts’ estimates. Its non-GAAP profit of $2.44 per share was in line with analysts’ consensus estimates.

Bark (NYSE:BARK) Reports Q4 In Line With Expectations But Stock Drops

Pet products provider Bark (NYSE:BARK) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 1.1% year on year to $126.4 million. On the other hand, next quarter’s revenue guidance of $126.2 million was less impressive, coming in 1.9% below analysts’ estimates. Its non-GAAP loss of $0.02 per share was in line with analysts’ consensus estimates.

Tenable (NASDAQ:TENB) Posts Better-Than-Expected Sales In Q4 But Full-Year Sales Guidance Slightly Misses Expectations

Cybersecurity software maker Tenable (NASDAQ:TENB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 10.5% year on year to $235.7 million. On the other hand, next quarter’s revenue guidance of $233 million was less impressive, coming in 1.1% below analysts’ estimates. Its non-GAAP profit of $0.41 per share was 19% above analysts’ consensus estimates.

CONMED (NYSE:CNMD) Beats Q4 Sales Targets But Stock Drops

Medical tech company CONMED (NYSE:CNMD) announced better-than-expected revenue in Q4 CY2024, with sales up 5.8% year on year to $345.9 million. On the other hand, the company’s full-year revenue guidance of $1.36 billion at the midpoint came in 2.7% below analysts’ estimates. Its non-GAAP profit of $1.34 per share was 11.4% above analysts’ consensus estimates.